EU To Recognise Good Manufacturing Practice From Domestic Pharmaceutical Firms

In a positive development for Israeli drugmakers, the EU will recognise that Good Manufacturing Practices adopted within the country are sufficient not to warrant additional testing when drugs are exported to Europe. BMI notes that this cuts costs for Israel's pharmaceutical firms and will boost drug exports.

To read the full article, please choose one of the following options: